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ABSTRACT
Mutation-driven activation of KRAS is crucial to cancer development. The human 
gene yields four mRNA splicing isoforms, 4A and 4B being translated to protein. Their 
different properties and oncogenic potential have been studied, but the mechanisms 
deciding the ratio 4A/4B are not known. To address this issue, the expression of the 
four KRAS isoforms was determined in 9 human colorectal cancer cell lines. HCT116 
and SW48 were further selected because they present the highest difference in the 
ratio 4A/4B (twice as much in HCT116 than in SW48). Chromatin structure was 
analysed at the exon 4A, characteristic of isoform 4A, at its intronic borders and at the 
two flanking exons. The low nucleosome occupancy at exon 4A in both cell lines may 
result in a fast transcriptional rate, which would explain the general lower abundance 
of isoform 4A, also found in cells and tissues by other authors, but due to its similarity 
between both cell lines, chromatin structure does not influence alternative splicing. 
DNA methylation downstream exon 4A significantly differs in HCT116 and SW48 
cells, but the CCCTC-binding factor, which affects the processivity of RNA polymerase 
and the alternative splicing, does not bind the differentially methylated sequences. 
Quantitative epigenetic analysis at mononucleosomal level revealed significant 
differences between both cell lines in H3K4me3, H3K27me3, H3K36me3, H3K9ac, 
H3K27ac and H4K20me1, and the inhibition of some histone-modifying enzymes alters 
the ratio 4A/4B. It can be concluded that the epigenetic modification of histones has 
an influence on the selection of isoforms 4A and 4B.
INTRODUCTION
Human KRAS locus is located in chromosome 12 
(25,204,789-25,250,936) and is transcribed from the 
reverse strand. Four mRNA isoforms, which result from 
alternative splicing, are reported in the Ensembl Genome 
database (accession number ENSG00000133703). Two 
of these mRNA isoforms are translated to protein, giving 
rise to the well-known KRAS-4A and KRAS-4B products. 
The two remaining mRNA isoforms contain open reading 
frames and may be putatively translated, but the actual 
existence of their protein products has not been reported 
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to date. The first 164 residues of KRAS-4A and KRAS-4B 
are identical, but the C-terminal regions of the molecules 
(25 amino acids in isoform KRAS-4A and 24 in KRAS-
4B), encoded by different exons, show a high variability. 
KRAS-4A and KRAS-4B are members of the Ras protein 
family, which also includes the highly homologous HRAS 
and NRAS. All of these proteins display GTPase activity 
and are involved in signalling pathways that regulate many 
cellular processes, including cell proliferation.
The functional cellular environment of the KRAS 
isoforms is the plasma membrane [1, 2], in which they are 
anchored through the farnesyl chains posttranslationally 
added at a C-terminal motif [3]. Isoform 4A is further 
directed to membrane by palmitoylation of a specific 
cysteinyl residue [4] and a sequence containing 7 lysines 
also contributes to the membrane localization of KRAS-4B 
through electrostatic interactions with the inner leaflet of the 
plasma membrane [2]. The function of the latter topogenic 
signal is regulated by the phosphorylation of serine 181, 
which is interspersed in the basic stretch [5]. KRAS-4A 
is directed to its final location via the Golgi system, while 
KRAS-4B goes from the endoplasmic reticulum to the 
plasma membrane through a different mechanism, which 
involves phosphodiesterase-δ [6, 7]. The structural bases 
for specific KRAS-4B/ phosphodiesterase-δ interaction 
have been recently studied [8].
The isoforms KRAS-4A and KRAS-4B behave in a 
different way in many other aspects. For instance, while 
the expression of KRAS-4B is ubiquitous in human tissues 
[9, 10], that of KRAS-4A is restricted to the gastrointestinal 
tract, kidney, lung and other tissues of endodermal origin 
[9] and similar results were obtained in mice [11, 12]. As 
to the oncogenic potential of both isoforms there is some 
discrepancy in the data recorded in the literature. It is clear 
that the ratio of both isoforms is altered in cancer [9] and, 
while the focus-inducing potential of KRAS-4B is lower 
than that of KRAS-4A, the latter isoform do not induce 
cell migration and KRAS-4B does [13]. These early 
results are in agreement with those of King et al., who 
found that knockdown of KRAS-4A reduces proliferation 
of renal cell carcinoma [10]. However, after the results 
obtained in mice, KRAS-4A is classically considered to 
be proapototic, whereas KRAS-4B is antiapoptotic [14].
At any rate, it is clear that changes in the ratio of 
splicing isoforms 4A and 4B exist when comparing their 
expression levels in different cell lines or tissues, but the 
results reported in the literature are also controversial. It 
has been described that the ratio KRAS-4A/KRAS-4B is 
significantly reduced in 6 CRC cell lines when compared 
with cells derived from normal colon and in tumour from 
4/9 patients with sporadic CRC when compared with 
the adjacent normal mucosa [9] and similar results were 
obtained in adenomas of mouse small intestine in the 
absence of KRAS -activating mutations [15]. In agreement 
with these results, Chung et al., by transfecting mouse 
livers with different KRAS constructs, found that the 
survival of mice carrying mutation-activated KRAS-4A is 
significantly better than that of animals transfected with 
mutated KRAS-4B [16] and Luo et al. propose that the 
exon specifically included in KRAS-4A confers the gene 
a certain tumour-suppressor function [17]. The above 
data suggest that mutation-activated KRAS4B is more 
oncogenic than activated KRAS4A, and yet there are some 
discordant views in the literature. For instance, Wang et 
al. reported that increase of the ratio KRAS-4A/KRAS-4B 
in murine lung correlated with higher susceptibility to 
tumour development [12] and a major role in mouse lung 
carcinogenesis has been ascribed to KRAS-4A [18]. It has 
also been described that the expression of this isoform in 
human colorectal cancer and adenomas is higher than in 
the adjacent normal tissues [19].
Whatever the causes of the above discrepancies, it 
seems clear that it is worth studying the factors that decide 
the proportion of KRAS isoforms. Differential splicing is 
affected by many factors, including chromatin structure 
and epigenetic modifications near the splicing sites (for 
reviews, see [20, 21]). None of these factors have been 
studied in the human KRAS locus, although there is 
evidence that cis-acting elements, presumably located in 
introns or in 3’-untranslated regions decide the balance 
between KRAS-4A and KRAS-4B in murine lung cancer 
[22]. These circumstances prompted us to investigate the 
distribution of KRAS isoforms, including the non-coding 
ones, which might possess a regulatory role, in human 
CRC cell lines and to determine the chromatin structure 
and its epigenetic modifications in the regions involved in 
the selection among the different isoforms.
RESULTS
Expression of KRAS isoforms in different cell 
lines
To facilitate the interpretation of the results, a map 
of the human KRAS locus is given in Figure 1. The four 
possible transcripts are identified by the isoform number 
and code included in the ENSEMBL database. The 
conventional exon numbering, which correspond only to 
the translated ones (see, for instance, ref. [23]), is used. 
The untranslated exon present upstream of exon 1 in 
all the isoforms is further referred to as exon 0 and the 
exon downstream exon 1, characteristic of isoform 2, is 
designed as 1’.
We first quantified the transcription of whole KRAS 
in 9 CRC cell lines (Figure 2A) using primers from exon 
0, common to all mRNA isoforms. The relative abundance 
of each four transcripts was then determined (Figure 2B). 
To differentiate among the four isoforms we designed 
the primers given in Supplementary Table 1. Isoform 1 
(4B) was analysed with a forward primer from exon 3 
and a reverse primer spanning exons 3 and 4B. Isoform 
2 was quantified by using a forward primer from exon 
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1 and a reverse primer from exon 1’, which is unique 
to this isoform. To analyse isoform 3, a forward primer 
from exon 1 and a reverse one spanning exons 1 and 4B 
were used. Finally, isoform 4 (4A) was quantified with a 
forward primer from exon 4A, which is present only in 
this isoform, and a reverse primer from 5’ end of exon 4B. 
The location of those primers is depicted in Supplementary 
Figure 1. To correct for the possible differences in the 
efficiency of the primers, we determined the efficiency 
factors, which are also given in Supplementary Table 
1. The slight differences in efficiency did not affect the 
results of the RT-qPCR experiments given in Figure 2B.
The expression of whole KRAS is highly variable 
from line to line, being higher in Caco2 and lower in RKO 
and SW48. The expression level is roughly similar in 
lines HCT116 and DLD1 and the cells derived from these 
parental lines show a lower expression level, although 
a slight compensatory effect for the loss of one of the 
alleles seems to occur (Figure 2A). The expression of the 
individual isoforms, relative to ACTB, is given in Figure 
2B. Isoform 1 (4B) is the most abundant in all the cell 
lines studied; present results agree with those of Tsai et 
al. [23]. The level of isoform 3 is negligible in all the cell 
lines, but the expression of the non-translated isoform 2 is 
comparable, or even slightly higher than that of isoform 
4 (4A).
In view of the above mentioned interest of studying 
the mechanisms deciding the relative abundance of 
the different splicing isoforms of KRAS, especially the 
isoforms 1 (4B) and 4 (4A), we selected the cell lines 
SW48 and HCT116. This selection was based in the fact 
that they are the lines showing a greater difference in the 
ratio between both isoforms. This is especially apparent in 
Figure 2C, in which the percentage of the four isoforms 
is given. The percentage of isoform 4 (4A) in HCT116 
doubles that in SW48 at the expense of isoform 1 (4B), 
Figure 1: Schematic representation of the human KRAS locus. (A) map of the entire locus in which the exons are depicted as 
boxes and identified in the widespread manner, which only numbers the translatable exons (1 to 4B). The 5’ non-translatable exon present in 
all mRNA isoforms is designed as exon 0, and the non-translatable exon downstream of exon 1, is numbered as 1’. The numbers below the 
scale give, in base pairs, the absolute position within the locus. (B) mRNAisoforms resulting from alternative splicing, identified with the 
number given in the text (bold lettering) and with the Ensembl Genome database numbering; black boxes indicate the translatable exons. 
(C) map of the two known protein products of the gene, showing the common (orange) and the variable sequences.
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Figure 2: Transcription level of the whole KRAS gene and of its isoforms in several human CRC cell lines. (A) expression, 
relative to the ACTB gene, of the whole gene in 9 cell lines. (B) expression, relative to the ACTB gene, of the four isoforms in those cell 
lines. (C) percent expression of the four isoforms in HCT116 and SW48 cells. The results were obtained by RT-qPCR in triplicate and 
expressed as the mean ± standard deviation.
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while the proportion of isoform 2 is roughly similar in 
both cell lines and that of isoform 3 is negligible. In other 
words, exon 6 (4A) is skipped in SW48 cells twice more 
than in HCT116 cells.
Chromatin structure at the differential splicing sites of 
HCT116 and SW48 cell lines
Taking into account that the chromatin structure 
is a factor influencing the splicing events [20], the 
nucleosomal organization of the KRAS locus in exons 
3 and 4A and in the translatable 5’ end of exon 4B was 
studied. These regions include the adjacent splicing 
sites and other potential sequences that may influence 
inclusion or skipping of exon 4A. The micrococcal 
nuclease protection data, obtained at the amplicons 
defined in Supplementary Table 2, are compatible with 
the occupancy of the three exons by nucleosomes. The 
size of the exons is, respectively, 165, 124 and 117 bp, 
so there is room in them for a single nucleosome, and the 
width of the protected areas are also compatible with the 
presence of a single nucleosome over each exon (Figure 
3A-3C). The sequence-based prediction retrieved from 
the NuPop program is compatible with the presence 
of nucleosomes over exons 3 and 4A, but not with the 
presence of a nucleosome in the 5’ end of exon 4B, in 
which the probability of assembling a nucleosome is very 
low, in accordance with the high content of A and T in 
that region. In spite of these circumstances, the results 
suggest that the nuclease protection observed in the 5’ end 
of exon 4B (Figure 3C) is actually due to the presence 
of a nucleosome. As it will be shown later, the Nuc-ChIP 
experiments gave positive results at the amplicon centred 
at position 41600 and a quantitative determination of the 
concentration of H3 by using a Nuc-ChIP assay with an 
antibody against the C-terminal end of the histone gave 
at least twice as much H3 over the exon 4B than over 
the exon 4A. Thus, it is highly probable that the nuclease 
protection at the 5’ end of exon 4B is due to the presence 
of a bona fide nucleosome.
The profiles of micrococcal nuclease protection 
are almost identical in HCT116 and SW48 cell lines, and 
only a slight difference is observed in the nucleosome 
occupancy over exon 4B. Within the resolution margin 
of this assay, the flanks of the exons, which contain the 
3’ and 5’ splicing sites, as well as the polypyrimidine 
tract immediately upstream of the 5’ sites, seem to be 
unprotected in both cell lines and, then, accessible to the 
spliceosome assembly. In view of the above results, it 
seems that the chromatin structure has no influence on the 
differences in exon 4A skipping between both cell lines.
DNA methylation downstream of exon 4A
DNA methylation can also affect exon skipping in 
several ways [24]. To check whether distinct methylation 
levels may be the cause of the differential level of KRAS 
isoforms 4 (4A) and 1 (4B) in HCT116 and SW48, we 
analysed DNA methylation downstream of exon 4A. As 
shown in Figure 4, there is a single CpG dinucleotide 
within exon 4A and this low CpG content may be related 
to its low nucleosome occupancy (see Figure 3B) [25]. 
Several CpG sites are clustered in the downstream intron 
starting approximately at 500 bp 3’ to exon 4A, but only 
6 out of these sites could be analysed to quantify their 
methylation degree following the used procedure (Figure 
4B). Subtle, but significant, differences between SW48 
and HCT116 cell lines were observed in the three CpG 
sites analysed between 36700 and 36870, which showed a 
more intense methylation in HCT116 (Figure 4A).
The possibility that these differences in methylation 
resulted in a distinct CCCTC-binding factor (CTCF) 
recruitment was next studied, as it has been described 
that the presence of bound CTCF downstream of exons 
Figure 3: Nucleosome occupancy at the exons involved in alternative splicing in HCT116 and SW48 cells. (A) exon 3. (B) 
exon 4A. (C) exon 4B. The plots give the nuclease protection in arbitrary units against the position of each amplicon centre in the locus. The 
maps below identify the exon location as black rectangles. In (C), the gray rectangle refers to the non-translatable, transcribed exon. The 
results correspond to three determinations for each amplicon (Panels A and C) or to six determinations from two independent experiments 
(Panel B) and are given as the mean ± standard deviation. ** p<0.01.
Oncotarget20583www.oncotarget.com
causes a diminution of the elongation rate of RNA pol II, 
which in turn may affect the inclusion of the exon due 
to kinetic factors [24]. ChIP analysis, followed by qPCR 
evaluation of amplified sequences, revealed that CTCF 
does not appreciably bind the region studied. Actually, the 
concentration of DNA sequences immunoprecipitated with 
an anti-CTCF antibody is similar to that recovered without 
added antibody (Supplementary Table 3).
Epigenetic modification of histones in the regions 
involved in alternative splicing
Taking into account that splicing usually is a co-
transcriptional event, it is known that the presence of some 
epigenetic marks in nucleosomes surrounding the splicing 
sites may influence exon skipping and/or inclusion [20, 
21]. As the differences in the selection between the 4A 
and 4B KRAS isoforms in HCT116 and SW48 cell lines is 
not probably determined by chromatin structure or CTCF 
binding, the differential presence of epigenetic marks in 
the nucleosomes covering exons 3, 4A and 4B was next 
studied by the Nuc-ChIP procedure. The following histone 
post-translational modifications (PTMs) were analysed: 
H3K4me3, H3K9me3, H3K27me3, H3K36me3, H3K9ac, 
H3K27ac and H4K20me1. These histone PTMs rank 
among the marks most frequently associated with splicing 
events (see [26] and references therein). Two independent 
Nuc-ChIP experiments were carried out at the amplicons 
corresponding to the three nucleosomes positioned on 
exons 3, 4A and 4B. The PCR quantifications were done in 
triplicate in both experiments. With only an exception (see 
below), the differences in the studied epigenetic marks 
between HCT116 and SW48 cells were not significant in 
exons 3 and 4A, while most of them were significant in 
the nucleosome covering exon 4B.
Only the results giving significant differences 
between HCT116 and SW48 cell lines are depicted in 
Figure 5. The comparison of the results with the marks 
on H3K27 provides an internal control of the validity of 
the experiments, because the trends of acetylation and 
methylation run in the opposite direction, as expected for 
two mutually exclusive PTMs.
H3K27ac is the only epigenetic mark which 
shows significant differences in the three nucleosomes 
studied, being more intense in the three exons in HCT116 
Figure 4: Methylation level of CpGs downstream exon 6 (4A) in HCT116 and SW48 cell lines. (A) the level of methylation 
in a quantitative scale (average of 5-10 determinations) is plotted against the position of the analysed CpGs in the locus; the CpGs showing 
a significant difference (p<0.05) between both cell lines are identified. (B) map showing the position of the CpGs; filled circles indicate 
those analysed for their methylation level, while empty circles refer to those CpGs, which could not be analysed by the method used. The 
amplicons used to evaluate CpG methylation are shown in green, and those used for qPCR analysis of CTCF binding are represented in 
blue.
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cells. These cells are also more heavily marked in the 
nucleosome covering exon 4B in four out of the other 
histone PTMs that show significant differences, namely 
H3K4me3, H3K36me3, H3K9ac and H4K20me1. Only 
H3K27me3 is more intense in SW48 than in HCT116 
(Figure 5). To check whether differences in histone 
epigenetic modifications are actually related to alternative 
splicing, the ratio of isoforms 4A/4B was studied after 
inhibiting histone deacetylases with trichostatin A 
(TSA), and EZH1/2 histone methyltransferases with 
EPZ005687. Inhibition of the latter enzymes was selected 
because they specifically catalyse the methylation of 
H3K27. As the other methylatable lysines studied in the 
experiment of Figure 5 are modified by several redundant 
methyltransferases [27], inhibition of all of them results in 
cell lethality. As expected, treatment with TSA increases 
the acetylation level of bulk H3 and EPZ005687 reduces 
the methylation of H3K27 (Supplementary Figure 2). 
Figure 6 shows that reducing the level of H3K27me3 
causes a significant increase in the 4A/4B ratio in the 
SW48 cell line. In both cell lines, the TSA-induced change 
of H3 acetylation leads to significant changes in the 4A/4B 
ratio, which resulted levelled after the treatment.
DISCUSSION
The results described in the present paper add 
some details to our knowledge on the distribution of 
KRAS isoforms and on the mechanisms involved in their 
selection. First, in spite of the differences in the expression 
of the whole gene observed among the different cell lines 
analysed (Figure 2A), isoform 1 (4B) is the more abundant 
in every case (Figure 2B). With a few exceptions, this is 
a common feature in both, cell lines and human normal 
and cancerous tissues [9, 17, 23]. The splicing variants 2 
and 3 have received little or no attention in the literature. 
The fact that the translation of their mRNAs had not 
been demonstrated to date may be a cause for that lack 
of interest.
As far as we know, present paper describes for the 
first time a study of the distribution of those isoforms 
in several CRC cell lines. The presence of isoform 3 is 
negligible in all the cell lines studied, but isoform 2, which 
includes exon 1’ and a premature transcription termination 
signal (Figure 1), is clearly detectable. It is known that 
a non-translatable mRNA splice variant of HRAS, which 
includes the otherwise skipped exon 5, plays a regulatory 
role in the expression of the gene [28], and it would be 
interesting to know whether KRAS isoform 2 performs a 
similar role.
The differences in the ratio between isoforms 1 
(4B) and 4 (4A) among the different cell lines found in 
the present paper, as well as the differences observed by 
many authors, put forward the question as to what splicing 
regulatory mechanisms decide between the inclusion or 
skipping of exon 4A in the mature transcript. In fact, exons 
4A and 4B cannot be regarded as mutually exclusive exons 
at the level of mature mRNA, because the 5’ end of exon 
4B is present in the mature transcript of both isoforms 
1 (4B) and 4 (4A). In the latter isoform, exon 4B is not 
translated, because the included exon 4A contains a stop 
codon (TAA) in the 3’ end.
Intron and exon definition may obey to two different 
mechanisms, occurring either at the level of the mRNA 
precursor, or at the DNA level [21]. Taking into account 
that in most cases splicing is a cotranscriptional event, the 
second mechanism seems to be the most common one. 
In this case, chromatin structure plays a fundamental 
role. Nucleosomes are usually positioned in exons and 
their presence causes RNA polymerase to reduce its 
processivity [29], helping the splicing factors to be 
recruited to the nascent pre-mRNA [21].
To investigate the mechanisms deciding the 
inclusion of exon 4A, a comparison of the chromatin 
Figure 5: Nuc-ChIP analysis of histone epigenetic modifications in nucleosomes located over the exons 3, 4A and 4B. 
Only those histone PTMs that significantly differ between HCT116 and SW48 cells are depicted. Three independent Nuc-ChIP experiments 
were carried out and the figure gives the results of one representative experiment. qPCR analysis were carried in triplicate and the mean ± 
standard deviation is plotted. * p<0.05; ** p<0.01; *** p<0.001.
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structure of the HCT116 and SW48 cells was first done. 
Of note, although the differences between both cell lines 
are negligible, the nucleosome occupancy is lower at exon 
4A than at the other exons. It is also much lower than in 
the proximal regions of the flanking introns (Figure 3B), 
so the processivity of RNA polymerase II is not reduced at 
its passage through exon 4A. Interestingly, the presumably 
fast processivity of RNA polymerase II through exon 4A 
may explain why the isoform containing this exon is less 
abundant than isoform 1 (4B) in all the cell lines studied 
in the present paper as well as in the patient samples and 
cell lines analysed by other authors [23].
The epigenetic differences between HCT116 
and SW48 cell lines in the regions of interest to the 
present study were also examined. It is known that 
CpG methylation of DNA and histone PTMs can affect 
splicing through the “recruitment coupling” model [20]. 
For instance, DNA methylation at CpG dinucleotides 
prevents the binding of CTCF at overlapping target 
sites of the factor. As CTCF represents an obstacle to 
RNA polymerase II processivity, CTCF binding at non-
methylated CpG containing sites favours the inclusion 
of weak upstream exons [30]. Nevertheless, the present 
results (Figure 4 and Supplementary Table 3) allowed us 
to conclude that CTCF-dependent kinetic factors do not 
represent a main mechanism to decide the inclusion of 
exon 4A.
Finally, the histone PTMs were analysed by Nuc-
ChIP in the three nucleosomes positioned over the exons 
3, 4A and 4B. We have previously used this technique 
[31, 32] and its advantages have been recently reviewed 
[33]. Most of the significant differences in histone PTMs 
between HCT116 and SW48 cell lines are found in the 
nucleosome positioned in exon 4B (Figure 5).
The experiment of Figure 6 supports the hypothesis 
that changes in histone PTMs result in an alteration of 
the alternative splicing events. The enhancement of the 
acetylation of H3 is associated with a significant increase 
in the 4A/4B ratio in SW48 cell line (Figure 6B), in which 
the low level of H3 acetylation (Figure 5) is linked to a 
low 4A/4B ratio. SW48 cells are characterized by a high 
level of H3K27me3 (Figure 5) and a lower 4A/4B ratio 
and, therefore, a diminution of methylation might well be 
linked to an increase of the isoform ratio. The effects of 
inhibiting EZH1/2 histone methyltransferases on HCT116 
cells are not so easy to explain. Anyway, the results of 
Figure 6 clearly shows that the histone PTMs examined 
are in some way responsible for the discrimination 
between KRAS 4A and 4B isoforms.
It is not an easy task to ascribe the differences in 
the isoform ratio to a given epigenetic mark. In spite of 
the efforts that have been carried out in the last years to 
find a splicing code (for an early proposal, see [34]), an 
unambiguous correlation between histone epigenetic 
marks and splicing events does not exist. Many of the 
studies in that sense have been carried out by means of 
genomic approaches [35] and, while the information 
provided by these methods is highly valuable from a 
statistical point of view, particular genes may not obey to 
those general rules.
The differences in histone PTMs between HCT116 
and SW48 cells shown in Figure 5 are mainly confined 
Figure 6: Effects of the changes in the level of H3 acetylation and H3K27 methylation on the KRAS 4A/4B ratio. TSA 
was used to inhibit histone deacetylases and EPZ005687 to inhibit EZH histone methyltransferases. (A) HCT116 cell line. (B) SW48 cell 
line.
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to the nucleosome over the exon 4B. The question 
arouses as to whether epigenetic differences in exon 
4B may cause, in some way, the observed differential 
skipping of exon 4A. The recruitment model [36–38] 
provides a plausible hypothesis to explain the influence 
of epigenetic modifications of the nucleosome over exon 
4B on the skipping of the upstream exon. This model 
assumes that some histone PTMs recruit, through an 
adaptor, a splicing regulator that, in turn, binds a target 
regulatory site in nascent pre-mRNA. The present fine 
analyses at mononucleosomal resolution may be relevant 
to deepen the knowledge of the splicing epigenetic code 
and of the relationships between histone modifications 
and cancer progression. In this way, novel candidate 
therapeutic targets might be eventually found, by using 
either epigenetic modulators [39], or drugs targeted to the 
splicing machinery [40].
MATERIALS AND METHODS
Cell lines
The human CRC cell line HCT116 (ATCC CCL-
247) and their derivatives HAE6 (a gift from Dr B. 
Vogelstein) and HAF1m [41], DLD1 (ATCC CCL-
221) and their derivatives D-Mut1 (a gift from Dr B. 
Vogelstein) and DWT7m [42] were grown in McCoy's 5A 
medium (Sigma, St. Louis, MO, USA). The cell lines RKO 
(Horizon Discovery, Cambridge, UK) and Caco-2 (ATCC 
HTB-37) were grown in Dulbecco's modified Eagle's 
medium (DMEM) and the cell line SW48 (Horizon), was 
grown in RPMI 1640 medium (Sigma). All media were 
supplemented with 10% heat inactivated foetal bovine 
serum, 1% penicillin-streptomycin and 1% L-glutamine 
(Sigma), and the cultures were maintained under standard 
conditions. Table 1 shows the relevant genotypes and 
sources of the cell lines. The cell lines obtained from other 
authors were not further authenticated.
To inhibit histone modifying enzymes, cells were 
loaded in 6-well plates and treated with either 0.25 μM TSA 
(Sigma) or 20 μM EPZ005678 (Selleckchem) for 24 h.
Determination of transcript levels
RNA extraction, retrotranscription to cDNA and 
qPCR were carried out as previously described [42], using 
the β-actin gene (ACTB) as standard. The primers used 
for whole KRAS and for the different transcripts resulting 
from alternative splicing are given in Supplementary 
Table 1. The isoforms are identified by their number in 
the ENSEMBL database, followed in the case of isoforms 
1 and 4, by the more widespread nomenclature 4B and 4A 
in brackets.
To determine the efficiency of each qPCR primer 
set, a standard curve was prepared. The Ct values for 
serial template dilutions of cDNA are plotted against the 
logarithm of the dilution factor and the calculated slope 
gives a measure of the efficiency factor, which was used 
for normalization to compare the results obtained at 
different amplicons.
Analysis of chromatin structure
Nucleosome occupancy was determined by the 
micrococcal nuclease protection assay [32], using tiled 
amplicons of about 100 bp in size. The primers used are 
given in Supplementary Table 2. The experimental results 
were compared with the output of the sequence-based 
prediction of positioning carried out using the NuPoP 
software tool [43].
Table 1: Cell lines used in this paper
Cell line 
Relevant genotype
Source 
KRAS BRAF PIK3CA TP53
DLD1
D-Mut1
DWT7m
G13D/wt
G13D/-
G12D*/-
wt E545K; D549N S241F
ATCC CCL-221
Dr Vogelstein
Riffo-Campos et 
al. [24]
HCT116
HAE6
HAF1m
G13D/wt
G13D/-
A146T/-
wt H1047R wt
ATCC CCL-247
Johns Hopkins 
University
Roda et al. [23]
RKO wt V600E H1047R wt Horizon Discovery
SW48 wt wt wt wt Horizon Discovery
Caco2 wt wt wt E204X ATCC HTB-37
The parental cell lines are represented in bold characters and, when appropriate, the mutant variant is listed below them. 
The mutation marked by an asterisk affects only 20% of cell population.
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Analysis of DNA methylation
Quantitative DNA methylation analysis was 
carried out essentially as described by Coolen et al.[44]. 
Briefly, the method uses a T7-promoter-tagged PCR 
amplification of bisulphite-modified DNA, followed 
by generation of a single-stranded RNA molecule and 
subsequent base-specific cleavage (3′ to either rUTP or 
rCTP) by RNase A. The mixture of cleavage products, 
which differ in length and mass, are analysed by 
MALDI-TOF-MS. Changes in nucleotide sequence after 
bisulphite treatment, which reflects the differences in 
the methylation profile of original DNA, give origin to 
different fragment masses in the assay. The abundance 
of each fragment (signal/noise level in the spectrum) 
is indicative of the amount of DNA methylation in the 
analysed sequence.
Previously, bisulphite treatment of genomic DNA 
(1 μg) was carried out with the EZ-96 DNA methylation 
kit (Zymo Research), following the manufacturer’s 
protocol. For quantitative methylation analysis an 
AGENA’s MassARRAY platform was used. PCR primers 
for the amplification of the different regions of the KRAS 
locus downstream of exon 4A were designed by using 
Epidesigner (AGENA) and their sequences and location 
were given, respectively, in Supplementary Table 4 and 
Figure 4B.
The PCRs were carried out in a 5 μl format with 
10 ng/μl bisulfite-treated DNA, 0.2 units of TaqDNA 
polymerase (AGENA), 1 × Taq buffer, and 200 nM PCR 
primers. Dephosphorylation of unincorporated dNTPs 
was performed as recommended by the manufacturer. The 
reaction mixtures were further diluted with 20 μl of H2O 
and conditioned with 6 mg of CLEAN Resin (AGENA) 
for optimal mass-spectra analysis.
Chromatin immunoprecipitation (ChIP)
To investigate the binding of CCCTC-binding 
factor (CTCF) to chromatin, ChIP analysis was carried 
out after sonicating the chromatin to an average 
fragment size of 250-300 bp following the previously 
described procedure [45, 46]. The sequences of primers 
used for qPCR were given in Supplementary Table 5 
and their location is depicted in Figure 4B. Although the 
amplicons are not tiled, the average size of chromatin 
fragments ensured that CTCF is absent from the entire 
region under consideration. Epigenetic modifications 
of histones were studied at nucleosomal level by 
Nuc-ChIP [31, 32]. The following antibodies were 
used: anti-H3K9ac (Abcam, ab-4441); anti-H3K9me3 
(Abcam, ab-8898); anti-H3K27ac (Abcam, ab-4729); 
anti-H3K27me3 (Millipore, 07-449); anti-H3K4me3 
(Abcam, ab-8580); anti-H3K36me3 (Abcam, ab-9050); 
anti-H3K20m (Abcam, ab-9051); anti-β-actin (Abcam, 
ab-8227).
Statistical analysis
Quantitative values are expressed as mean ± SD. 
Data in the different PCR determinations were compared 
by two-tailed t-test. Differences were considered 
significant at p<0.05.
ACKNOWLEDGMENTS
The valuable aid of Dr Enrique Busó in DNA 
methylation analysis is greatly acknowledged. We thank 
Dr B. Vogelstein for the gift of the D-Mut1 cell line. 
CIBERONC is an initiative of the Carlos III Health 
Institute.
CONFLICTS OF INTEREST
The authors declare that no conflicts of interests 
exists.
GRANT SUPPORT
This work was supported by a grant from Generalitat 
Valenciana (PROMETEO 2013-005 to A.C.). ALR-C was 
a fellow of the Grisolia (2012/034) program.
REFERENCES
1. Hancock JF. Ras proteins: different signals from different 
locations. Nat Rev Mol Cell Biol. 2003; 4:373–84.
2. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in 
developmental disorders and cancer. Nat Rev Cancer. 2007; 
7:295–308.
3. Hancock JF, Magee AI, Childs JE, Marshall CJ. All 
ras proteins are polyisoprenylated but only some are 
palmitoylated. Cell. 1989; 57:1167–77.
4. Laude AJ, Prior IA. Palmitoylation and localisation of RAS 
isoforms are modulated by the hypervariable linker domain. 
J Cell Sci. 2008; 121:421–27.
5. Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis 
MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, Yim 
D, Fein A, Pérez de Castro I, et al. PKC regulates a farnesyl-
electrostatic switch on K-Ras that promotes its association 
with Bcl-XL on mitochondria and induces apoptosis. Mol 
Cell. 2006; 21:481–93.
6. Weise K, Kapoor S, Werkmüller A, Möbitz S, Zimmermann 
G, Triola G, Waldmann H, Winter R. Dissociation of 
the K-Ras4B/PDEδ complex upon contact with lipid 
membranes: membrane delivery instead of extraction. J Am 
Chem Soc. 2012; 134:11503–10.
7. Schmick M, Vartak N, Papke B, Kovacevic M, Truxius DC, 
Rossmannek L, Bastiaens PI. KRas localizes to the plasma 
membrane by spatial cycles of solubilization, trapping and 
vesicular transport. Cell. 2014; 157:459–71.
Oncotarget20588www.oncotarget.com
8. Dharmaiah S, Bindu L, Tran TH, Gillette WK, Frank PH, 
Ghirlando R, Nissley DV, Esposito D, McCormick F, 
Stephen AG, Simanshu DK. Structural basis of recognition 
of farnesylated and methylated KRAS4b by PDEδ. Proc 
Natl Acad Sci USA. 2016; 113:E6766–75.
9. Plowman SJ, Berry RL, Bader SA, Luo F, Arends MJ, 
Harrison DJ, Hooper ML, Patek CE. K-ras 4A and 4B are 
co-expressed widely in human tissues, and their ratio is 
altered in sporadic colorectal cancer. J Exp Clin Cancer Res. 
2006; 25:259–67.
10. King S, Bray S, Galbraith S, Christie L, Fleming S. 
Evidence for aldosterone-dependent growth of renal cell 
carcinoma. Int J Exp Pathol. 2014; 95:244–50.
11. Plowman SJ, Williamson DJ, O’Sullivan MJ, Doig J, 
Ritchie AM, Harrison DJ, Melton DW, Arends MJ, 
Hooper ML, Patek CE. While K-ras is essential for mouse 
development, expression of the K-ras 4A splice variant is 
dispensable. Mol Cell Biol. 2003; 23:9245–50.
12. Wang Y, You M, Wang Y. Alternative splicing of the K-ras 
gene in mouse tissues and cell lines. Exp Lung Res. 2001; 
27:255–67.
13. Voice JK, Klemke RL, Le A, Jackson JH. Four human ras 
homologs differ in their abilities to activate Raf-1, induce 
transformation, and stimulate cell motility. J Biol Chem. 
1999; 274:17164–70.
14. Plowman SJ, Arends MJ, Brownstein DG, Luo F, Devenney 
PS, Rose L, Ritchie AM, Berry RL, Harrison DJ, Hooper 
ML, Patek CE. The K-Ras 4A isoform promotes apoptosis 
but does not affect either lifespan or spontaneous tumor 
incidence in aging mice. Exp Cell Res. 2006; 312:16–26.
15. Patek CE, Arends MJ, Rose L, Luo F, Walker M, Devenney 
PS, Berry RL, Lawrence NJ, Ridgway RA, Sansom OJ, 
Hooper ML. The pro-apoptotic K-Ras 4A proto-oncoprotein 
does not affect tumorigenesis in the ApcMin/+ mouse small 
intestine. BMC Gastroenterol. 2008; 8:24.
16. Chung SI, Moon H, Ju HL, Kim DY, Cho KJ, Ribback 
S, Dombrowski F, Calvisi DF, Ro SW. Comparison of 
liver oncogenic potential among human RAS isoforms. 
Oncotarget. 2016; 7:7354–66. https://doi.org/10.18632/
oncotarget.6931.
17. Luo F, Ye H, Hamoudi R, Dong G, Zhang W, Patek CE, 
Poulogiannis G, Arends MJ. K-ras exon 4A has a tumour 
suppressor effect on carcinogen-induced murine colonic 
adenoma formation. J Pathol. 2010; 220:542–50.
18. To MD, Wong CE, Karnezis AN, Del Rosario R, Di Lauro 
R, Balmain A. Kras regulatory elements and exon 4A 
determine mutation specificity in lung cancer. Nat Genet. 
2008; 40:1240–44.
19. Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi 
S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud 
S, Al-Dayel F, Uddin S, Al-Kuraya KS. Prognostic 
significance of alterations in KRAS isoforms KRAS-4A/4B 
and KRAS mutations in colorectal carcinoma. J Pathol. 
2009; 219:435–45.
20. Kornblihtt AR, Schor IE, Alló M, Dujardin G, Petrillo E, 
Muñoz MJ. Alternative splicing: a pivotal step between 
eukaryotic transcription and translation. Nat Rev Mol Cell 
Biol. 2013; 14:153–65.
21. Naftelberg S, Schor IE, Ast G, Kornblihtt AR. Regulation of 
alternative splicing through coupling with transcription and 
chromatin structure. Annu Rev Biochem. 2015; 84:165–98.
22. Dassano A, Colombo F, Trincucci G, Frullanti E, Galvan A, 
Pettinicchio A, De Cecco L, Borrego A, Martinez Ibañez 
OC, Dragani TA, Manenti G. Mouse pulmonary adenoma 
susceptibility 1 locus is an expression QTL modulating 
Kras-4A. PLoS Genet. 2014; 10:e1004307.
23. Tsai FD, Lopes MS, Zhou M, Court H, Ponce O, Fiordalisi 
JJ, Gierut JJ, Cox AD, Haigis KM, Philips MR. K-Ras4A 
splice variant is widely expressed in cancer and uses a 
hybrid membrane-targeting motif. Proc Natl Acad Sci USA. 
2015; 112:779–84.
24. Lev Maor G, Yearim A, Ast G. The alternative role of DNA 
methylation in splicing regulation. Trends Genet. 2015; 
31:274–80.
25. Gelfman S, Ast G. When epigenetics meets alternative 
splicing: the roles of DNA methylation and GC architecture. 
Epigenomics. 2013; 5:351–53.
26. Hu Q, Kim EJ, Feng J, Grant GR, Heller EA. Histone 
posttranslational modifications predict specific alternative 
exon subtypes in mammalian brain. PLoS Comput Biol. 
2017; 13:e1005602.
27. Michalak EM, Visvader JE. Dysregulation of histone 
methyltransferases in breast cancer - Opportunities for new 
targeted therapies? Mol Oncol. 2016; 10:1497–515.
28. Barbier J, Dutertre M, Bittencourt D, Sanchez G, Gratadou 
L, de la Grange P, Auboeuf D. Regulation of H-ras splice 
variant expression by cross talk between the p53 and 
nonsense-mediated mRNA decay pathways. Mol Cell Biol. 
2007; 27:7315–33.
29. Jimeno-González S, Payán-Bravo L, Muñoz-Cabello AM, 
Guijo M, Gutierrez G, Prado F, Reyes JC. Defective histone 
supply causes changes in RNA polymerase II elongation 
rate and cotranscriptional pre-mRNA splicing. Proc Natl 
Acad Sci USA. 2015; 112:14840–45.
30. Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski 
B, Kashlev M, Oberdoerffer P, Sandberg R, Oberdoerffer 
S. CTCF-promoted RNA polymerase II pausing links DNA 
methylation to splicing. Nature. 2011; 479:74–79.
31. Sacilotto N, Espert A, Castillo J, Franco L, López-Rodas 
G. Epigenetic transcriptional regulation of the growth 
arrest-specific gene 1 (Gas1) in hepatic cell proliferation 
at mononucleosomal resolution. PLoS One. 2011; 
6:e23318.
32. Riffo-Campos ÁL, Castillo J, Tur G, González-Figueroa 
P, Georgieva EI, Rodríguez JL, López-Rodas G, Rodrigo 
MI, Franco L. Nucleosome-specific, time-dependent 
changes in histone modifications during activation of the 
Oncotarget20589www.oncotarget.com
early growth response 1 (Egr1) gene. J Biol Chem. 2015; 
290:197–208.
33. Castillo J, López-Rodas G, Franco L. Histone post-
translational modifications and nucleosome organisation in 
transcriptional regulation: some open questions. Adv Exp 
Med Biol. 2017; 966:65–92.
34. Barash Y, Calarco JA, Gao W, Pan Q, Wang X, Shai O, 
Blencowe BJ, Frey BJ. Deciphering the splicing code. 
Nature. 2010; 465:53–59.
35. Spies N, Nielsen CB, Padgett RA, Burge CB. Biased 
chromatin signatures around polyadenylation sites and 
exons. Mol Cell. 2009; 36:245–54.
36. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T. 
Epigenetics in alternative pre-mRNA splicing. Cell. 2011; 
144:16–26.
37. Sims RJ 3rd, Millhouse S, Chen CF, Lewis BA, Erdjument-
Bromage H, Tempst P, Manley JL, Reinberg D. Recognition 
of trimethylated histone H3 lysine 4 facilitates the 
recruitment of transcription postinitiation factors and pre-
mRNA splicing. Mol Cell. 2007; 28:665–76.
38. Gunderson FQ, Johnson TL. Acetylation by the 
transcriptional coactivator Gcn5 plays a novel role in 
co-transcriptional spliceosome assembly. PLoS Genet. 
2009; 5:e1000682.
39. Kelly AD, Issa JJ. The promise of epigenetic therapy: 
reprogramming the cancer epigenome. Curr Opin Genet 
Dev. 2017; 42:68–77.
40. Bonnal S, Vigevani L, Valcárcel J. The spliceosome as a 
target of novel antitumour drugs. Nat Rev Drug Discov. 
2012; 11:847–59.
41. Roda D, Castillo J, Telechea-Fernández M, Gil A, López-
Rodas G, Franco L, González-Rodríguez P, Roselló S, 
Pérez-Fidalgo JA, García-Trevijano ER, Cervantes A, 
Zaragozá R. EGF-induced acetylation of heterogeneous 
nuclear ribonucleoproteins is dependent on KRAS 
mutational status in colorectal cancer cells. PLoS One. 
2015; 10:e0130543.
42. Riffo-Campos Á, Castillo J, Vallet-Sánchez A, Ayala G, 
Cervantes A, López-Rodas G, Franco L. In silico RNA-seq 
and experimental analyses reveal the differential expression 
and splicing of EPDR1 and ZNF518B genes in relation to 
KRAS mutations in colorectal cancer cells. Oncol Rep. 
2016; 36:3627–3634.
43. Xi L, Fondufe-Mittendorf Y, Xia L, Flatow J, Widom J, 
Wang JP. Predicting nucleosome positioning using a duration 
Hidden Markov Model. BMC Bioinformatics. 2010; 11:346.
44. Coolen MW, Statham AL, Gardiner-Garden M, Clark 
SJ. Genomic profiling of CpG methylation and allelic 
specificity using quantitative high-throughput mass 
spectrometry: critical evaluation and improvements. 
Nucleic Acids Res. 2007; 35:e119.
45. Sandoval J, Rodríguez JL, Tur G, Serviddio G, Pereda J, 
Boukaba A, Sastre J, Torres L, Franco L, López-Rodas 
G. RNAPol-ChIP: a novel application of chromatin 
immunoprecipitation to the analysis of real-time gene 
transcription. Nucleic Acids Res. 2004; 32:e88.
46. Tur G, Georgieva EI, Gagete A, López-Rodas G, Rodríguez 
JL, Franco L. Factor binding and chromatin modification in 
the promoter of murine Egr1 gene upon induction. Cell Mol 
Life Sci. 2010; 67:4065–77.
